Bruce Randazzo

Bruce Randazzo

Company: AnaptysBio

Job title: Vice President Clinical Development


A Novel Drug Candidate for Alopecia Areata: An Anti-BTLA Modulator 12:10 pm

Detailing the mode of action for checkpoint inhibitor modulation in chronic inflammatory dermatological disease Cataloguing the dermatological diseases to approach with checkpoint inhibitor modulation Considering endpoints: pharmacodynamics, moving trials beyond 16 weeks (how to know if we have truly reset the immune system), and psycho/social aspects of a life-limiting diseaseRead more

day: Day 2 AM - Track B

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.